The Pharmacology of Longevity: Peptide Edition (Part 1) In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 Erectile Dysfunction: Exploring the Peptide's Potential Role FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Peptide BPC 157 Does It Work? Breaking Down the Evidence and the Hype